Trastuzumab (Herceptin®; Genentech, San Francisco, CA, USA) is a recombinant humanized monoclonal antibody IgG1 targeting human epidermal growth factor receptor-2 (HER2) and has substantially improved the prognosis of HER2-positive breast cancer [12]. This evidence concerns the gene ERBB2 and breast cancer.